Chicken or the Egg? Why We Need to Rethink Data and Funding in Startups

Opinions expressed by Entrepreneur contributors are their own.

During the early days of COVID-19, companies like Moderna and Pfizer demonstrated the

speed and scale at which biopharma can transform healthcare. But this wasn’t an anomaly.

Despite ongoing societal disruption and a shifting geopolitical landscape, the biopharma industry continues to innovate, reshaping how we approach disease and improving the quality of life.

One of the biggest challenges these companies face, however, is securing funding. Traditional

models require founders to raise capital from multiple sources, making a strong pitch essential, but the true linchpin of any startup is the data and evidence behind the idea.

A compelling pitch paired with robust data creates a narrative that resonates with investors, demonstrating not just vision but measurable potential. The paradox is that generating this evidence often requires funding in the first place.

This creates a critical early-stage challenge: startups must secure capital before they have sufficient data to fully validate their ideas. To overcome this, founders need to strike a careful balance of building a credible narrative that highlights potential while reducing uncertainty for investors.

Ultimately, success at this stage depends on aligning storytelling, evidence and trust

to establish the foundation for long-term growth.

... continue reading